Pharmacogenomics

Setting future standards for KRAS testing in colorectal cancer
pp. 1-3(3)
Authors: van Krieken, Han; Tol, Jolien

News & Views in Pharmacogenomics
pp. 5-7(3)

Interview
pp. 9-12(4)
Author: Klein, Roger D

Research Highlights
pp. 13-16(4)
Authors: Veraitch, Ophelia; Stebbing, Justin

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
pp. 17-28(12)
Authors: LLerena, Adrián; Dorado, Pedro; Peñas-Lledó, Eva M

Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with Type 2 diabetes mellitus Cardiovasc
pp. 29-34(6)
Authors: Manfredi, Samantha; Calvi, Debora; del Fiandra, Martina; Botto, Nicoletta; Biagini, Andrea; Andreassi, Maria Grazia

A Bayesian approach to gene-gene and gene-environment interactions in chronic fatigue syndrome
pp. 35-42(8)
Authors: Lin, Eugene; Hsu, Sen-Yen

Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece
pp. 43-49(7)
Authors: Ragia, Georgia; Arvanitidis, Kostas I; Tavridou, Anna; Manolopoulos, Vangelis G

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients
pp. 51-57(7)
Authors: Payne, Rachel E; Yagüe, Ernesto; Slade, Martin J; Apostolopoulos, Christos; Jiao, Long R; Ward, Becky; Coombes, R Charles; Stebbing, Justin

EGFR-targeted therapies in lung cancer: predictors of response and toxicity
pp. 59-68(10)
Authors: Heist, Rebecca Suk; Christiani, David

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
pp. 69-80(12)
Authors: Danesi, Romano; Altavilla, Giuseppe; Giovannetti, Elisa; Rosell, Raffael

Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration
pp. 81-95(15)
Authors: Parmeggiani, Francesco; Gemmati, Donato; Costagliola, Ciro; Sebastiani, Adolfo; Incorvaia, Carlo

Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach
pp. 97-108(12)
Authors: Vosslamber, Saskia; van Baarsen, Lisa GM; Verweij, Cornelis L

4th US FDA-Drug Information Association pharmacogenomics workshop, held 10-12 December, 2007
pp. 111-115(5)
Authors: Frueh, Felix W; Salerno, Ronald A; Lesko, Lawrence J; Hockett, Richard D

Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV - Breakout Session 1
pp. 117-125(9)
Authors: Armstrong, Martin; Bromley, Christina; Cohen, Nadine; Hunt, Christine M; O'Neill, Robert; Power, Aidan

Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop
pp. 127-136(10)
Authors: Hinman, Lois; Spear, Brian; Tsuchihashi, Zenta; Kelly, James; Bross, Peter; Goodsaid, Federico; Kalush, Francis

Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with `what-ifs'
pp. 137-147(11)
Authors: Surh, Linda C; Lesko, Lawrence J; Hobbs, Stuart; Gutman, Steve; Minasian, Lori M; Pasqua, Oscar E Della; Austin, MJ Finley; Lu, Kan

Payer perspectives on pharmacogenomics testing and drug development
pp. 149-151(3)
Authors: Epstein, Robert S; Frueh, Felix W; Geren, Dawn; Hummer, Doris; McKibbin, Scott; O'Connor, Susan; Randhawa, Gurvaneet; Zelman, Benjamin

Acknowledgements
pp. 155-155(1)